fbpx
May 8, 2023

Eyenovia’s Mydcombi Gets FDA Nod for Pupil Dilation Eyenovia’s Mydcombi Gets FDA Nod for Pupil Dilation

The US Food and Drug Administration (FDA) has approved Mydcombi (Eyenovia) for the dilation of pupils during diagnostic procedures. The ophthalmic spray, made of 1% tropicamide […]
May 8, 2023

FDA Staff Raises Concerns Over OTC Use of Birth Control Pill FDA Staff Raises Concerns Over OTC Use of Birth Control Pill

(Reuters) -The U.S. health regulator’s reviewers on Friday raised concerns around allowing Perrigo Co’s birth control drug over the counter, saying switching to non-prescription sale could […]
May 8, 2023

Mohs Surgery Workforce Continues to Increase Mohs Surgery Workforce Continues to Increase

SEATTLE — At least for now, the number of physicians trained to perform Mohs surgery is not only stable but appears to be increasing. New findings […]
May 8, 2023

Study of Hospitalizations Shows COVID-19 Vaccine Benefit Study of Hospitalizations Shows COVID-19 Vaccine Benefit

A cohort study of more than 1.5 million hospital admissions in Canada through the first 2 years of the COVID-19 pandemic has quantified the benefit of […]
May 8, 2023

Colchicine’s 2010 Price Spike Had Major Impact on Gout Care Colchicine’s 2010 Price Spike Had Major Impact on Gout Care

A large price increase for colchicine in 2010 led to a significant falloff in its use for gout that persisted for the next decade while emergency […]
May 8, 2023

AI Improves Mammography Accuracy, Reduces Workload AI Improves Mammography Accuracy, Reduces Workload

The study covered in this summary was published on ssrn.com as a preprint and has not yet been peer reviewed. Key Takeaway Artificial intelligence (AI)–assisted mammography […]
May 8, 2023

Olanzapine Effective for Higher-Risk Chemo-Induced Nausea Olanzapine Effective for Higher-Risk Chemo-Induced Nausea

The addition of olanzapine (Zyprexa) to standard antiemetic therapy among patients receiving highly emetogenic chemotherapy provides better nausea and vomiting relief across subgroups at high risk […]
May 8, 2023

Phase 3 Trial: Maribavir Yields Post-Transplant Benefits Phase 3 Trial: Maribavir Yields Post-Transplant Benefits

The effects of maribavir (Levtencity) for the treatment of resistant or refractory post-transplant cytomegalovirus (CMV) infection persisted at 52-week follow-up in hematopoietic stem cell and solid […]
May 8, 2023

High Follistatin Predicts Poor Cardiometabolic Outcomes High Follistatin Predicts Poor Cardiometabolic Outcomes

The study covered by this research summary was published on Preprints With The Lancet as a preprint and has not yet been peer reviewed. Key Takeaways […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640641642643644645646647648649650651652653654655656657658659660661662663664665666667668669670671672673674675676677678679680681682683684685686687688689690691692693694695696697698699700701702703704705706707708709710711712713714715716717718719720721722723724725726727728729730731732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792793794795796797798799800801802803804
Next page
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0